Where are your products exported?

Our products are exported to over 70 countries in Asia, Europe, Africa, and the Americas.

What is the shelf life or warranty?

Specific shelf life details are not provided in the description, but products meet strict quality standards.

What is the nearest shipping port?

The nearest port for shipping is Qingdao Port.

Reyoung Pharma/Cefazolin Sodium for Injection/GMP/OEM

Name: Reyoung Pharma/Cefazolin Sodium for Injection/GMP/OEM
Brand: Reyoung Pharmaceutical Co., Ltd.
SKU: 1957747902

Shandong, ChinaReyoung Pharmaceutical Co., Ltd.

Negotiable

10,000 vial

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

for Injection

Model NO.

0.5g; 1.0g

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Powder

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Lu20160062

Drug Ad Approval No.

Lu20160062

Certificate

GMP, SGS, ISO

Transport Package

10vials/Tray/Box, 50vials/Tray/Box.

Specification

0.5g, 1.0g

Trademark

Reyoung

Origin

China Reyoung

HS Code

3003909090

Production Capacity

5million Vials/Year

Key features

GMP Certified Manufacturing: Produced in GMP, ISO9001, ISO14001, and OHS18001 certified facilities.

OEM and ODM Services: Full OEM and ODM services available for customized pharmaceutical needs.

Global Market Coverage: Products exported to over 70 countries across Asia, Europe, Africa, and Americas.

High Production Capacity: Annual capacity of 2.5 billion vials of powder for injection and 4 billion tablets.

Broad Therapeutic Application: Treats respiratory, urinary, skin, bone infections, septicemia, and surgical prophylaxis.

Strict Quality Control: Meets rigorous standards for sterility, endotoxins, and assay uniformity.

International Certifications: Passed GMP inspections in Colombia, Peru, Ethiopia, Nigeria, and other nations.

Established Manufacturer: Leading Chinese pharmaceutical manufacturer established in 1966 with 5000+ staff.

Company profile

Reyoung Pharmaceutical Co., Ltd.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2020-10-13 CertifiedNearest Port: Qingdao PortAverage Response Time: ≤24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryReyoung Pharmaceutical Co., Ltd. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The available information identifies it as a pharmaceutical manufacturer supplying injectable antibiotics, oral solid medicines, veterinary cefotaxime sodium sterile, and lyophilized products. It reports more than 10 production lines, 370 years of combined R&D engineer experience, 50 quality-control staff, and ISO9001, ISO14001, and ISO45001 certifications. Export sales represent 31%–40% of total sales, with exporting reported since 2020 in one record and since 1998 in the company description, creating a discrepancy. Trade records show limited documented transactions and associated buyers in Bolivia, India, and Vietnam. Evidence is insufficient to assess after-sales service, financial credibility, customization, or verified customer performance comprehensively.

Supplier typeThe supplier is identified as a limited company and pharmaceutical manufacturer based in Shandong, China. Its stated products include injectable cephalosporins and penicillins, oral solid medicines, lyophilized products, and veterinary medicines, indicating a combined manufacturing and commercial business profile.

CertificationsThe supplier reports ISO9001:2015, ISO14001:2015, and ISO45001:2016 management-system certificates, along with cGMP, PIC/S, and ANVISA GMP holdings. These claims directly support established quality, environmental, occupational-safety, and pharmaceutical GMP capability, although certificate validity and scope are not independently shown.

R&D capabilityThe supplier reports 370 years of total R&D engineer experience and offers multiple dosage forms and pharmaceutical categories, including lyophilized products and injectable antibiotics. These details support R&D resources and product-development breadth, but no information confirms proprietary technologies, new product launches, patents, or development outcomes.

Production capacityProduction capability is supported by 4,950 employees, more than 10 production lines, pharmaceutical manufacturing descriptions, and product records for injectable antibiotics and veterinary cefotaxime sodium sterile. The plant-area entry is recorded as 0.0m², which is unusable or inconsistent data, so facility scale cannot be confirmed from that field.

Client casesTrade-related records associate the supplier with buyers in Bolivia, India, and Vietnam and show documented transactions for oral rehydration products, cefotaxime acid, and ceftriaxone sodium for injection. The records show some international commercial activity, but the number of stated transactions is limited and no customer testimonials, repeat-order evidence, or performance evaluations are provided.